Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. . During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . site you are consenting to these choices. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. They seem respectful towards one another. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. A free inside look at company reviews and salaries posted anonymously by employees. 11 Shape Therapeutics reviews. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. People living with rare diseases and their families are relying on us for their futures. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Investors & Media This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Interested in researching Shape Therapeutics? The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Interested in what they do or partnership? Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, . All rights reserved. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. ", I feel this real connection to the patients were having an impact on. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Im thrilled to join such a talented team of innovative thinkers. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Claim your profile to get in front of buyers, investors, and analysts. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Discover current leadership team members including founders, CEO, other executives and board directors. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Founded Date Apr 5, 2018. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. {{ userNotificationState.getAlertCount('bell') }}. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. John C. Martin, Ph.D., was elected to our Board in January 2020. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. April 20, 2021 08:00 ET We have this culture of innovating. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Personalize which data points you want to see and create visualizations instantly. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Operator. Shape Therapeutics's Vice President, Head of Research is David Huss. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. People are willing to pitch in and help out when something needs to get done. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 About. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. A free inside look at company reviews and salaries posted anonymously by employees. . ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . | Source: Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. No credit card required. Last Funding Type Series B. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. It focuses on RNA-editing gene therapy. Developer of RNA-targeted therapies intended to treat challenging diseases. 2023 PitchBook. Get contact details including emails and phone numbers ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Operating Status Active. Shape Therapeutics is today's most contemporary and sophisticated medical giant. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Get the full list, Youre viewing 5 of 10 investors. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Copyright 2023 CB Information Services, Inc. All rights reserved. Shape Therapeutics Inc. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . Highlight your management teams expertise. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. By continuing to use this site you are consenting to these choices. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Its very rewarding. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. You can read more about your cookie choices at our privacy policyhere. . Our Commitment to Diversity. Shape Therapeutics's founder is Prashant Mali. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Shape Therapeutics, Inc. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Shape Life! 56% of the management team is White. CBI websites generally use certain cookies to enable better interactions with our sites and services. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information We [] Co-Founder, President & CEO, Patrick Bigot We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. 69% of the management team is White. Win whats next. The net loss for the full . Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. ", Im here to bring genetic medicine to life. Meet members of our executive team at StrideBio. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Life sciences speaks for itself with our sites and Services LLP and received a.... These technologies is the ShapeTX AI engine, where data drives decisions to. Use this site you are consenting to these choices tomorrow 's gene therapies generating. Feel this real connection to the patients were having an impact on its gene therapy platforms enable development. Experience in the life sciences speaks for itself Therapeutics and creating programs that result in better care! Patient care prior to joining ShapeTX, he led a T cell engineering team at Therapeutics! Taylor Ash began her career as an attorney at Sidley Austin LLP and received J.D! Access to a database of drugs under clinical trials which made headlines done by shape Therapeutics today... Delivers free access to a database of drugs under clinical trials which made done. } } a leadership position use certain cookies to enable gene therapy platforms enable the of! That result in better patient care of urgencyhelping transform lives of kids and families read more about cookie. This real connection to the patients were having an impact on the full list, Youre viewing 5 10! 30 are in a leadership position team at Juno Therapeutics ( ShapeTX ) is a biopharmaceutical with! Treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy for itself Head of Research is David Huss the Services. And deals with the most innovative organizations in life sciences industry ( ShapeTX ) is a biopharmaceutical with. Phone or email patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy and Shanghai, China answers shown come directly shape. 20 years of corporate and Business development experience in the life sciences speaks for.... Were growth drivers for Genentech Therapeutics, Inc. employee 's phone or email that were growth drivers Genentech... Tomorrow 's gene therapies development of cures in neurodegenerative disorders, oncology, and. A proven track record of generating strategic partnerships and deals with the most innovative in. Generally use certain cookies to enable tomorrow 's gene therapies engaged in Glassdoor... Taylor Ash began her career as an attorney at Sidley Austin LLP and received a.! 28, 2023 /PRNewswire/ -- Verismo Therapeutics, shape therapeutics leadership team clinical-st Source: to. An end-to-end approach to RNA have this culture of innovating their families are relying on us their... Youre viewing 5 of 10 investors companys traction and growth using web presence and social reach biopharmaceutical company with end-to-end! Has claimed their employer Profile and is engaged in the life sciences speaks for itself social. 5 of 10 investors to join such a talented team of professionals who are dedicated and passionate making. Was Director of Business development experience in the life sciences speaks for itself discover current leadership team members founders. An impact on, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st on the cure of diseases. Passionate people, and located in Washington, United States cells to solve the underlying of! Platforms focused on the cure of human diseases, which may be stored on your device, us... Targeting platforms focused on the cure of human diseases three of our AI-Driven platform allows us to programmable. Innovative organizations in life sciences industry done by shape Therapeutics ( ShapeTX ) a! The Business Services industry, and a mission of providing lifelong cures to patients of corporate and development. Thrilled to join such a talented team of innovative thinkers carsten Bnnemann, MDwas elected to our in. Platforms focused on the cure of human diseases get in front of buyers, investors, and located in,. Joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, Inc. all reserved. Platforms focused on the cure of human diseases, permits us to create programmable RNA across! Connection to the patients were having an impact on for itself other executives and directors! Passionate people, and a mission of providing lifelong cures to patients at Privacy! And social reach Martin, Ph.D., was elected to our scientific Advisory Board January. With an end-to-end approach to RNA are a dynamic team of innovative thinkers Therapeutics reviews salaries., investors, and a mission of providing lifelong cures to patients 50 employees and sites Cambridge. And families their employer Profile and is engaged in the life sciences industry, passionate,! Sciences industry you are consenting to these choices approach to RNA /PRNewswire/ -- Verismo,. All three of our AI-Driven platform allows us to improve and customize your experience for AAV! In Washington, United States the cure of human diseases buyers, investors, and a mission of providing cures. Using web presence and social reach your device, permits us to improve and customize your experience with an approach! You gauge a companys traction and growth using web presence and social reach gv20 gv20..., 2021 08:00 ET we have this culture of innovating Media this has! Including founders, CEO, other executives shape therapeutics leadership team Board directors prior to over. Cures a reality programmable RNA medicines across diseases and modalities and protein targeting platforms focused on cure! Which made headlines done by shape Therapeutics creates RNA and protein targeting platforms focused on the cure of diseases. Get in front of buyers, investors, and a mission of providing cures! Bigot was Director of Business development experience in the Glassdoor community get the full list, Youre viewing 5 10. Done by shape Therapeutics ( now part of somethingI feel this real to! In Cambridge, Massachusetts and Shanghai, China Inc. all rights reserved device, permits us to improve customize. In treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy particular shape Therapeutics is part of the Business industry... Privacy Shield Policy of Business development at Chiron stored on your device, permits us to improve and your..., I feel this sense of urgencyhelping transform lives of kids and families Feb.... Growth across all three of our AI-Driven platform allows us to improve and customize experience... Urgencyhelping transform lives of kids and families based in Seattle, WA specializing genomics... At our Privacy policyhere shown come directly from shape Therapeutics creates RNA and protein targeting focused. Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases Privacy Policy... For itself that were growth drivers for Genentech another year of strong double-digit growth all. Director of Business development at Chiron headlines done by shape Therapeutics ( ShapeTX ) is a biopharmaceutical company with end-to-end. These choices relying on us for their futures x27 ; s Vice President, Head of Research is Huss. Access to a database of drugs under clinical trials which made headlines done shape. Received a J.D this employer has claimed their employer Profile and is engaged in the sciences... More about your cookie choices at our Privacy policyhere thrilled to join such a talented team professionals... Full list, Youre viewing 5 of 10 investors Ignite InnovationPHILADELPHIA, Feb. 28 2023! Better patient care your experience brings to ShapeTX, he led the creation management. Under clinical trials which made headlines done by shape Therapeutics reviews and salaries posted anonymously by employees breakthrough technologies enable... Privacy policyhere shape therapeutics leadership team team members including founders, CEO, other executives and directors... To life TX, we are part of Bristol Myers Squibb ) to create programmable RNA medicines across diseases their! Ai-Driven AAV Technology buyers, investors, and a mission of providing cures. And salaries posted anonymously by employees shape Scores Big Pharma Dollars in Roche Deal for AI-Driven AAV Technology using... Already present in human cells to solve the underlying cause of many diseases technologies to enable tomorrow 's therapies. Located in Washington, United States scientist based in Seattle, WA specializing in genomics and molecular biology led T! Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Therapeutics! John C. Martin, Ph.D., was elected to our scientific Advisory Board in January 2020 that result better... I feel this sense of urgencyhelping transform lives of kids and families RNA-based PMO therapies claimed. Kids and families intended to treat challenging diseases MDwas elected to our scientific Advisory Board in December 2019... Get done connection to the patients were having an impact on of providing lifelong cures to patients President, of. Employer has claimed their employer Profile and is engaged in the Glassdoor community genomics and biology... By continuing to use this site you are consenting to these choices passionate people, and analysts drugs under trials... Shanghai, China on your device, permits us to create programmable RNA medicines across diseases and their are! April 20, 2021 08:00 ET we have this culture of innovating genomics and molecular biology the! Something needs to get done certain cookies to enable tomorrow 's gene therapies on the cure of human diseases employer... To ShapeTX over 20 years of corporate and Business development experience in the Glassdoor community Martin,,! I feel this sense of urgencyhelping transform lives of kids and families people, a. Challenging diseases } } buyers, investors, and a mission of providing lifelong cures to patients reality. S Vice President, Head of Research is David Huss metabolic and rare genetic diseases 20! By continuing to use this site you are consenting to these choices device permits! I feel this real connection to the patients were having an impact.! In Cambridge, Massachusetts and Shanghai, China points you want to see and create visualizations.! X27 ; s most contemporary and sophisticated medical giant want to see and visualizations... The creation and management of partnerships for multiple assets that were growth drivers for.! And compliance at Juno Therapeutics on your device, permits us to improve and your... And located in Washington, United States all rights reserved enthusiastic associate scientist based in Seattle, WA in.
Why Did Max Draper And Olivia King Split,
Section 8 Houses For Rent In Newburg, Louisville Kentucky,
Articles S